Cytokinetics Inc (NASDAQ:CYTK) Q1 2018 Sentiment

September 8, 2018 - By Richard Slagle

Cytokinetics, Incorporated (NASDAQ:CYTK) Logo

Sentiment for Cytokinetics Inc (NASDAQ:CYTK)

Cytokinetics Inc (NASDAQ:CYTK) institutional sentiment decreased to 0.88 in Q1 2018. Its down -0.23, from 1.11 in 2017Q4. The ratio dropped, as 49 funds opened new or increased stock positions, while 56 reduced and sold their positions in Cytokinetics Inc. The funds in our partner’s database now possess: 36.39 million shares, down from 38.16 million shares in 2017Q4. Also, the number of funds holding Cytokinetics Inc in their top 10 stock positions was flat from 1 to 1 for the same number . Sold All: 19 Reduced: 37 Increased: 30 New Position: 19.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company has market cap of $428.83 million. The firm is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. It currently has negative earnings. The Company’s lead drug candidate is Tirasemtiv, a fast skeletal troponin activator, which is in Phase III clinical trial in patients with amyotrophic lateral sclerosis.

The stock decreased 2.48% or $0.2 during the last trading session, reaching $7.85. About 145,861 shares traded. Cytokinetics, Incorporated (NASDAQ:CYTK) has declined 37.37% since September 8, 2017 and is downtrending. It has underperformed by 49.94% the S&P500.

Analysts await Cytokinetics, Incorporated (NASDAQ:CYTK) to report earnings on October, 25. They expect $-0.48 EPS, up 20.00 % or $0.12 from last year’s $-0.6 per share. After $-0.51 actual EPS reported by Cytokinetics, Incorporated for the previous quarter, Wall Street now forecasts -5.88 % EPS growth.

Bvf Inc Il holds 4.18% of its portfolio in Cytokinetics, Incorporated for 5.72 million shares. Ironwood Investment Management Llc owns 105,324 shares or 0.55% of their US portfolio. Moreover, Lansdowne Partners (Uk) Llp has 0.2% invested in the company for 2.65 million shares. The Utah-based Wasatch Advisors Inc has invested 0.16% in the stock. Pinnacle Associates Ltd, a New York-based fund reported 888,415 shares.

Since January 1, 0001, it had 0 buys, and 6 insider sales for $173,508 activity.

Cytokinetics, Incorporated (NASDAQ:CYTK) Ratings Coverage

Ratings analysis reveals 50% of Cytokinetics Inc’s analysts are positive. Out of 2 Wall Street analysts rating Cytokinetics Inc, 1 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $9 while the high is $2400. The stock’s average target of $16.50 is 110.19% above today’s ($7.85) share price. CYTK was included in 3 notes of analysts from April 27, 2018. The stock of Cytokinetics, Incorporated (NASDAQ:CYTK) earned “Buy” rating by H.C. Wainwright on Monday, June 18. The stock of Cytokinetics, Incorporated (NASDAQ:CYTK) has “Buy” rating given on Friday, April 27 by H.C. Wainwright. The firm has “Equal-Weight” rating given on Wednesday, August 1 by Morgan Stanley.

More news for Cytokinetics, Incorporated (NASDAQ:CYTK) were recently published by: Nasdaq.com, which released: “Cytokinetics Awards Inaugural Communications Fellowship To The ALS Association Golden West Chapter” on August 28, 2018. Globenewswire.com‘s article titled: “Cytokinetics to Present at the Morgan Stanley Global Healthcare Conference” and published on September 05, 2018 is yet another important article.

Cytokinetics, Incorporated (NASDAQ:CYTK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.